To Assess the Anti-anginal Safety and Efficacy of Ivabradine in Subjects With Stable,Symptomatic Chronic Angina
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 336 participants.
Also called NCT02623569
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 336 participants
- Sponsor
- Xintong Pharmacy Company
- Registry
-
NCT02623569
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT02623569. Randomized; quadruple masking; primary purpose treatment. Start 2014-10 (registry gives no type); primary completion 2017-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- To Assess the Anti-anginal Safety and Efficacy of Ivabradine in Subjects With Stable,Symptomatic Chronic Angina
- Condition
- Angina Pectoris
- Intervention (Drug)
- Ivabradine
- Intervention (Drug)
- Atenolol
- Lead sponsor
- Xintong Pharmacy Company
Record details
- Record id
cardio:ct-nct02623569- Content hash
c25245183d174f7bc3b18a07add077dab5580c079cc31ff0af59815326eeeb49